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     INTRODUCTION 
  The symposium was held on November 20, 2010, and 
included four plenary panels covering key subjects related to 
public sector research, investment in innovation, and access 
to technologies for neglected tropical diseases (NTDs). The 
four panels covered the following topics: (1) the current state 
of affairs in NTD research and technology transfer at pub-
lic institutions, including the role of academia in the medical 
innovation system from an industry perspective; (2) specific 
strategies and barriers to effective collaborations with prod-
uct development partnerships (PDPs) and industry; (3) novel 
funding mechanisms for research and development (R&D) 
programs, financial resources to sustain NTD research at uni-
versities, and new approaches to intellectual property to alter 
incentives for scientific innovation; and (4) the roles of open 
access publishing and open source (OS) scientific discovery 
for neglected infections of poverty. The details of each panel 
follow. 
   ACADEMIC  RESEARCH AND TECHNOLOGY 
TRANSFER 
  This panel introduced the global need for new treatment 
modalities, diagnostic technologies, and vaccines for NTDs. 
The panel also summarized current avenues of research in the 
field at universities and industry views regarding key ques-
tions that the public sector may be well-equipped to address. 
The discussion also focused on tools for bioinformatics and 
data sharing developed by the National Institutes of Health. 
  Gloria Tavera (MD/PhD candidate, Case Western Reserve 
University School of Medicine) began the symposium by 
addressing the role of universities in addressing NTDs. She 
highlighted that the gap in life expectancy between the richest 
and poorest countries in the last four decades has increased 
and that this health disparity should be a call to arms for sci-
entists, government leaders, medical product developers, and 
research trainees.  1   Tavera asserted that because universities 
have a stated commitment to act in the public interest, stu-
dents, academics, and university administrators are in a unique 
and powerful position to call for broader access to university 
research for low- and middle-income countries and answer 
research questions that address diseases of the poor. Tavera 
explained that widespread interest in global health at uni-
versities exists but must be harnessed in the form of concrete 
commitments—by addressing not only the big three (malaria, 
human immunodeficiency virus/acquired immunodeficiency 
syndrome [HIV/AIDS], and tuberculosis) but also the NTDs 
of extreme poverty.  2  
  Tavera highlighted that many mainstay treatments for 
NTDs are toxic, ineffective, and unsuitable for pediatric use. 
She cited the 2009 G-FINDER Report, which showed that, 
of the $3 billion US invested in research, only 0.4% was allo-
cated to NTD-related work.  3   She proposed that universities 
must join the National Institutes of Health (NIH), philan-
thropic donors, and developing countries in their efforts to 
increase research in this area. She encouraged universities to 
harmonize their efforts with NTD networks and global health 
initiatives for the dual purposes of enhancing awareness of 
disease-specific needs at the university and bolstering admin-
istrative support. Furthermore, she asserted that universities 
might also raise money for NTD research by creating seed 
funds in the spirit of existing country-level programs in which 
0.7% of national gross domestic products are donated to help 
reach the Millen  nium Development Goals. Tavera stated that 
NTD research training and education should be a priority 
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that may be actualized through training opportunities such 
as fellowships, symposia, and research collaborations with 
PDPs. One example of the pioneers on the NTD front that 
Tavera mentioned is the Henry Wheeler Center for Emerging 
and Neglected Diseases at the University of California at 
Berkeley, which promotes partnerships between the university 
and the Global South for the development of NTD-related 
biotechnology. 
  Tavera also asserted that students must continue to advo-
cate for universities to not only increase their commitments 
to NTD-related research but also ensure that resulting inno-
vations reach the populations that need them. Academic 
technology transfer offices can help by implementing equi-
table technology licensing strategies, including at cost provi-
sion or sublicensing terms for resource-limited countries. She 
described specific guidelines for achieving these goals as out-
lined by Universities Allied for Essential Medicines (UAEM) 
in the Global Access Licensing Framework,  4   a document that 
serves to guide university licensing practices. She added that 
a consensus document embracing many of these principles 
was adopted by 26 research institutions including the NIH, 
the Centers for Disease Control and Prevention, Harvard 
University, the University of North Carolina at Chapel Hill, 
and Yale University.  5  
 Mukul Ranjan (Chief, Immunology and Emerging Infectious 
Branch, National Institute of Allergy and Infectious Diseases, 
Office of Technology Transfer) began the panel by highlight-
ing that the NIH provides 40% of worldwide research funding 
for NTDs. Ranjan also stressed practices in open access and 
sharing that extend the funding dollar and create efficiencies 
that can be leveraged to facilitate NTD research. He outlined 
strides made by the NIH in open access science, starting with 
the establishment of GenBank in 1982, which made deposited 
gene sequences publicly accessible in an open digital reposi-
tory. Along a similar vein, in 1999, the Research Tools Sharing 
Policy strongly recommended that NIH-funded investigators 
share research materials; by 2003, the NIH required grantees 
awarded greater than $500,000 to provide and enact a data-
sharing plan.  6,  7   This policy was followed by a model organ-
ism sharing policy in 2004.  8   That same year, the NIH launched 
PubChem, mirroring GenBank, for sharing chemical struc-
tures, assays, and assay data. Ranjan noted that NIH public 
access sharing policy now mandates that manuscripts describ-
ing NIH-funded research be deposited into PubMedCentral, 
a free public repository, within 1 year of publication.  9   He 
explained that this policy was intended, in part, to enhance 
access to research by those people in resource-poor countries. 
  Ranjan shifted focus to the history of drug development. He 
explained that, previously, large public sector research insti-
tutions such as the NIH have traditionally focused on basic 
research. Therefore, moving basic discoveries forward to drug 
development depended overwhelmingly on the private sector, 
motivated essentially by market incentives alone. To preserve 
projects that often failed in an early phase of development—
the so-called valley of death—the NIH Molecular Libraries 
Initiative assembled compound libraries from academia and 
the private sector. It began to provide compound screen-
ing, protein production, assay development, and robotics 
facilities. 
  Ranjan highlighted that the NIH acknowledged the gaps in 
technologies for rare, orphan, or neglected diseases and there-
fore, established the Therapeutics for Rare and Neglected 
Diseases (TRND) Program in 2008 to enable private and 
public sector investigators to take lead compounds through 
preclinical testing. The program sought to evaluate five drug 
candidates every 6 months, allotting $5–10 million to each. Of 
note, one founding project focused on the NTD schistosomiasis, 
whereas the other four addressed rare diseases. Furthermore, 
Ranjan explained that all data and probes generated within 
TRND must be released to the public domain within 2 months 
of discovery. At the other end of the drug development pipe-
line, NIH contributed its intellectual property rights to the 
HIV drug darunavir to the Medicines Patent Pool, making it 
the first drug to be added. The Pool brings together patents to 
provide patients in low- and middle-income countries access 
to affordable and appropriate drugs. 
  Ranjan reminded the audience that the National Institute 
of Allergy and Infectious Diseases (NIAID) is the primary 
NIH institute that deals with infectious diseases and vaccine 
development, and it does so by supporting capacity building, 
training scientists, establishing research sites overseas, and 
assisting with Food and Drug Administration drug applica-
tions. In addition, he emphasized that the institute also main-
tained clinical trial sites for malaria, HIV, and other diseases 
and maintains free reagent repositories and support for pre-
clinical animal testing. 
  Ranjan ended with the most recent open access initiatives 
at NIAID, which included the establishment of the Human 
MicroBiome project,  10   the Eukaryotic Pathogen Database,  11  
and the Influenza Research Database.  12   Ranjan asserted that 
in doing so, the NIH recognizes that successful biomedical 
research will require approaching the massive inflow of data 
in a systematic way and providing broad access to research 
tools and ideas. 
  John Erickson (President and Chief Executive Officer, 
Sequoia Pharmaceuticals, Inc.) spoke on the potential roles for 
academia in drug innovation from a private sector standpoint. 
He believes the primary problem in drug innovation is that the 
cost for developing drugs for low-paying markets is the same 
as the cost for high-paying markets, whereas market incentives 
are much lower for the former. He highlighted that few drugs 
survive the R&D pipeline and that costs and risks increase 
dramatically as a drug advances through the stages of devel-
opment. He stated that universities are uniquely positioned to 
conduct operational research to improve R&D efficiency and 
reduce duplication of research, develop tools of pharmacology 
to better predict parameters such as solubility, and determine 
safety profiles of compounds at an early stage. He also noted 
that, for NTDs, more basic parasitology research is needed to 
identify drug targets and that academia may be able to best 
address this need. 
  Several common myths regarding R&D for NTDs need to 
be debunked, Erickson believed. First, he explained, the retail 
price of a patented drug is mistakenly thought to be related to 
its total cost of manufacture. In reality, the retail drug price is 
driven by market price—how much consumers are willing to 
pay. Second, Erickson asserted that patents do not necessarily 
block development of drugs and do provide protection for the 
investments made during drug development. Third, he argued 
that development of drugs for NTDs afflicting neglected peo-
ple was not inherently cheaper. He stated that, in actuality, 
regulations, safety, and efficacy data requirements incur sim-
ilar costs for drugs designed for developed and developing 
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  Erickson ended the panel by challenging biotechnology and 
pharmaceutical industries, academia, and nonprofit entities to 
develop drugs for neglected people both at home and abroad. 
He believed that a potential role for the NIH was exemplified 
by the National Cooperative Drug Discovery Group (NCDDG) 
for AIDS,  13   which provided multimillion dollar grants to 
researchers in both public and private domains to collaborate 
in translating basic research in retrovirology—including new 
drug targets—into drugs. In doing so, NCDDG succeeded in 
creating the first pharmaceutical agents active against viruses. 
Erickson asserted that NCDDG funding also allowed him and 
others to pursue the development of ritonavir and lopinavir, 
drugs that remain widely used for HIV treatment. He closed by 
suggesting that this same model should be applied to NTDs. 
   UNIVERSITIES,  PDPS, AND  INDUSTRY 
COLLABORATIONS 
  This panel featured leaders from academia and the PDP 
sector who have partnered with both universities and indus-
try to develop new technologies for leishmaniasis, hookworm, 
tuberculosis, and malaria. The panel highlighted the role that 
universities and university students can play in promoting the 
success of such collaborations. 
  Kishor Wasan (Cofounder/Director, Neglected Global 
Diseases Initiative and Professor, Faculty of Pharmaceutical 
Sciences, University of British Columbia) spoke about work-
ing as an academic scientist at the nexus of basic research 
and drug discovery and the challenges faced in founding the 
Neglected Global Diseases Initiative at the University of 
British Columbia (UBC). Wasan presented the following fun-
damental question: how can universities translate discoveries 
in the research laboratory to new technologies for the devel-
oping world? He emphasized that it is important for global 
health advocates to think about neglected people, not just 
neglected diseases, noting that this thought requires a multi-
disciplinary approach to also address inadequate healthcare 
delivery infrastructure and poor rates of retention of physi-
cians and medical scientists in developing countries.  14   These 
problems involve political, economic, and logistical issues. 
Wasan also highlighted other initiatives at UBC that address 
global health and development, including the Center for 
TB Research, the Health Technologies Access Program, the 
Center for International Child Health, and the Accessible 
Science Initiative. 
  Wasan stressed the need for greater funding and university 
encouragement to do NTD research and creativity in protect-
ing early discoveries to ensure adequate testing of early-stage 
compounds. He cited his own discovery of the novel lipid-
based oral formulation of amphotericin B used to treat vis-
ceral leishmaniasis and described its licensing by UBC to iCo 
Therapeutics.  15   Technology transfer policies in place at UBC 
ensured that this technology was made available at or below 
cost in least-developed countries.  16   In parallel, he explained 
that the drug would be marketed to treat systemic fungal 
infections in wealthy countries at a higher price. The prag-
matic advocacy approach taken by UBC students affiliated 
with UAEM was crucial to the adoption and successful imple-
mentation of the global access technology transfer policy at 
UBC. Wasan concluded by insisting that such efforts can best 
succeed at other universities by gaining the support of their 
most respected researchers. 
  Rita Khanna (Legal Counsel, Aeras Global Tuberculosis 
Vaccine Foundation) spoke about university partnerships with 
PDPs and the challenges faced by Aeras in collaborating with 
university laboratories and technology transfer offices. She 
indicated that barriers to the development of vaccines for dis-
eases of poverty, such as tuberculosis (TB), include the lack 
of vaccine development capacity in developing countries and 
the low profit margin for most vaccines. The existing Bacillus 
Calmette-Guérin (BCG) vaccine developed over 80 years 
ago is not effective in preventing adult pulmonary TB, and it 
has little to no effect in slowing the global TB epidemic.  17   The 
goal of Aeras is to have an efficacious TB vaccine on the mar-
ket within 7–10 years and make it available at affordable cost 
where it is needed most. 
  Khanna pointed out that there were more than 300 drugs 
in development for cancer and fewer than ten for TB in 
2006, despite the fact that one-third of the global population 
is infected with TB and close to 2 million people die annu-
ally.  18   To address this gap, PDPs such as Aeras have estab-
lished a new institutional framework for biomedical R&D 
to provide products for the developing world at the low-
est possible cost. Currently, Aeras is conducting a Phase IIb 
trial of a candidate TB vaccine at field sites in Africa in an 
effort involving at least two universities. This trial repre-
sents the farthest advance of any TB vaccine candidate in 
clinical testing since the introduction of BCG vaccine in the 
1930s. 
  Khanna explained that Aeras has collaborations with many 
organizations in academia, industry, government, and charita-
ble foundations. She emphasized that one barrier to success is 
the frequent practice in university technology transfer offices 
that require milestone payments from their PDP collaborators 
for incremental advances in development of the technology. 
Such requirements, Khanna stated, confer a heavy adminis-
trative and financial burden and consequently, pose a major 
difficulty for non-profit PDPs like Aeras. She asserted that 
milestone payments should be waived for licensees developing 
products for NTDs. Some universities have allowed royalties 
to be reinvested into future vaccine development and other 
R&D at Aeras. Furthermore, Khanna called on universities to 
measure their success based on the global impact of licensed 
technologies rather than focusing solely on revenue and 
royalties. 
  Neeraj Mistry (Managing Director, Global Network for 
Neglected Tropical Diseases, Sabin Vaccine Institute) spoke 
about the recent emergence of PDPs as important play-
ers in developing new technologies for NTDs. He explained 
that—unlike researchers working on HIV—those research-
ers working on NTDs have lacked an empowered com-
munity of advocates to drive the research agenda forward. 
This disadvantage, he asserted, was compounded by the 
fact that NTDs do not carry the same rates of mortal-
ity as do the big three of HIV, TB, and malaria, despite col-
lectively being a major driver behind the loss of global 
disability-adjusted life years, quality of life, and economic 
potential. 
  The Sabin Vaccine Institute was founded with the goal of 
developing vaccines for NTDs such as hookworm and schis-
tosomiasis. Although industry has played a large role in drug 
donation campaigns for NTDs, there remains an urgent need 
for new R&D. He also explained that the mission of Sabin 
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to encompass advocacy and outreach initiatives to guide and 
support the NTD research agenda. Mistry noted that Sabin 
also collaborates with the World Health Organization (WHO) 
to develop regional strategies for NTD control, focusing on 
horizontal platforms to strengthen health systems. As 501(c)
(3) non-profit organizations, PDPs such as Sabin are able to 
set their agendas based on global need rather than donor and 
shareholder mandates. 
  Mistry identified several important building blocks of a suc-
cessful PDP and movement around NTDs, including strong 
communication and organization between partners at differ-
ent institutions and among different sectors. In his opinion, 
organizations must also have a charismatic champion who 
can communicate effectively and inspire diverse collaborators, 
donors, and advocates. At Sabin, this champion is its president, 
Peter Hotez. 
  Mistry believes that academic research institutions are ide-
ally placed to serve as incubators of multisector efforts and 
are natural sites at which new business models and R&D par-
adigms can be cultivated. With respect to NTDs, universities 
could be doing more on all these fronts, along with improv-
ing and increasing the education that they offer relevant to 
the field. 
 Adam Richman (Senior Scientist, Sanaria, Inc.) spoke about 
the challenges and successes in development of an attenu-
ated vaccine for malaria using parasites irradiated in the early 
stage of their lifecycle. Sanaria has important collaborations 
both nationally and internationally with institutions in a vari-
ety of sectors. Its funders include the Institute for One World 
Health (iOWH), Medicines for Malaria Venture (MMV), 
Program for Appropriate Technology in Health (PATH), the 
US Department of Defense, and NIAID through the Small 
Business Innovation Research program. 
  Richman reported that malaria currently kills nearly 1 mil-
lion people and causes an estimated $12 billion of lost eco-
nomic activity each year.  19   Despite significant advances in 
prevention and treatment, he predicted that an effective 
prophylactic vaccine would likely be necessary to eliminate 
malaria in the face of rising drug resistance. Sanaria’s stated 
goal is to create a vaccine that is over 80% effective and deliv-
ered to the populations most in need. 
  Because malaria parasites move from the liver to the blood, 
Richman explained, blocking the late liver stage of parasitic 
development would be ideal to prevent progression from the 
liver to the blood stage and subsequent transmission of the 
parasite by mosquitoes. This model is unconventional because 
of the difficulty in manufacturing irradiated parasites in the 
pre-erythrocyte stage. Richman noted that regulatory chal-
lenges arise from the lack of knowledge about the correla-
tion between the animal model and human infection. In 2009, 
Sanaria submitted an Investigational New Drug application to 
the Food and Drug Administration for their PfSPZ vaccine 
candidate based on a non-replicating, attenuated sporozoite 
stage parasites administered through the intradermal or sub-
cutaneous route. Current efforts focus on optimizing dosing 
and administration, with the next clinical trial likely to explore 
intravenous administration. Although the intravenous route 
presents a significant challenge to access in many endemic 
regions, Sanaria will likely continue to optimize more feasi-
ble dosing routes. Finally, Richman reported that, although the 
vaccine must be stored in liquid nitrogen (another major bar-
rier in endemic areas), colleagues in Africa are optimistic that 
these barriers could be overcome if a truly efficacious vaccine 
were developed. 
   SUSTAINING  RESEARCH WITH  EMERGING 
GLOBAL INNOVATION INCENTIVES AND 
INTELLECTUAL PROPERTY MODELS 
  This panel highlighted innovative R&D programs and 
resources available for universities to finance and sustain 
NTD research. These resources include innovative approaches 
to intellectual property that aim to delink R&D financing 
from profits extracted downstream using proprietary intellec-
tual property frameworks. Both existing and proposed funding 
mechanisms were discussed. 
  James Love (Director, Knowledge Ecology International) 
spoke about new global innovation models and their appli-
cation to the university context. Many of these models aim 
to harness the global willingness to pay for R&D as a pub-
lic good and stimulate innovation while maintaining trans-
parency. Because the global markets offer little commercial 
incentive for innovators to address some of the world’s most 
pressing health needs, R&D funding should be delinked from 
the final cost of a product (i.e., high-end product prices should 
not be prerequisites to funding medicine R&D).  20   Such pro-
posals have been featured in WHO assembly resolutions,  21   but 
Love claims the rhetoric has been stronger than action. Both 
push mechanisms—such as grants to fund research—and pull 
incentives—such as innovation inducement prizes to replace 
product monopolies—are needed. He provided the following 
overview of incentives.  22,  23  
  The FDA seeks to stimulate research on drugs for orphan 
diseases by providing a 50% tax credit for the cost of clini-
cal trials.  24   Love pointed out that universities are tax-exempt 
institutions and therefore, not amenable to tax credit incen-
tives. Additional problems with the orphan drug designation, 
he continued, include a recent elimination of means testing 
(which helped to avoid exploitation by the innovating com-
pany) and lack of transparency regarding the amount of 
money needed to run a clinical trial.  25,  26   Another incentive, the 
priority review voucher (PRV), is meant to speed approval for 
future technologies as a reward for developing technologies to 
treat NTDs; however, this reward can be sought regardless of 
medical importance of the NTD medicine or whether the drug 
was already on the market.  27   To date, PRVs have only been 
granted for products already on the market, and therefore, 
their ability to spur new innovation is uncertain.  28   Of concern 
with both the orphan drug designation and the PRV, according 
to Love, are the lack of standards of transparency and access 
to the end products of the technology; no access provisions are 
required, and no mechanism exists to deal with abusive pric-
ing, despite the benefit provided by taxpayers.  29  
  Love then described advance market commitment pro-
grams and guarantees to buy products at fixed prices to stimu-
late R&D to address a clinical need. Recent examples include 
pandemic vaccine supplies,  30,  31   especially for pneumococcal 
disease.  32   According to Love, a market guarantee for the orig-
inal developer may not be sustainable in the long term and 
may negatively influence low-cost, local competitive produc-
ers. Another concern relating to access is that commitments 
are made without evaluation of cost/benefit of its exclusiv-
ity. Vaccine manufacturers, for example, receive 6 months of 
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no mechanism exists to deal with eventual price increases.  34  
Love claimed that advance market commitments also suffer 
from the common flaws of the orphan drug designation and 
the PRV: lack of transparency and no incentive to share data, 
materials, or technology.  35   These flaws could result, among 
other things, in restricting the number of producers who can 
ensure supply and generic competition to lower prices. 
  Love reminded the audience that large philanthropic 
granting foundations, with the Gates Foundation paramount 
among these groups, have mobilized enormous resources to 
address needs of the very poor; consequently, their influence 
both on global health priorities and access norms is substan-
tial. Because this influence may overshadow the role of public 
institutions, Love believes it deserves more discussion—in par-
ticular, addressing Gates’ opposition to the use of compulsory 
licensing and lack of support for the development of incentive 
mechanisms based on open licensing mechanisms.  36  
  Innovation inducement prizes are a pull incentive that 
rewards ideas deemed worthy of funding, typically in a com-
petitive process that includes many applicants.  20   Prizes may 
present more efficient incentives for drug development by 
enabling crowd-sourcing and rewarding precompetitive R&D. 
When access strategies are leveraged on the final products 
of research, they can bring lower prices to consumers of the 
end products. One example is the OS dividend (OSD), which 
aims to proportionally reward all contributors to a successful 
drug development initiative who openly share their databases, 
libraries, data repositories, and other materials.  37   Academic 
researchers could choose to partake in the OSD as an alter-
native, rather than a supplement, to traditional incentives 
(i.e., payments or royalties based on proprietary or restrictive 
licensing). The OSD has been included among R&D prize pro-
posals considered by the WHO,  38   and in the United States, this 
new incentive for openness and sharing has been introduced 
into the Senate (two bills  21  : S. 1137 and S. 1138) and would 
involve a portion of domestic drug sales to fund the OSD divi-
dend pool. Among all the mechanisms that he described, Love 
placed particular emphasis on evaluating implementation 
strategies for the OSD. 
  Additional incentives must address access issues in licens-
ing and patenting, proprietary versus restrictive practices, 
and secretiveness versus sharing in knowledge and research. 
According to Love, challenges for UAEM and other advocacy 
groups include setting standards for transparency within the 
medicines industry regarding scientific, medical, economic, 
and financial issues, particularly the disclosure of licensing 
terms. Without transparency, it is difficult to judge whether 
terms are properly crafted to be effective, pro-health incen-
tives. Furthermore, cost–benefit analyses of incentive pro-
grams are crucial to determine best practices. 
  Paul Wilson (Assistant Professor of Clinical Population 
and Family Health, Columbia University) spoke on innova-
tive incentive mechanisms, policy measures to solve the prob-
lem of R&D for NTDs, and strategies to ensure access to end 
products. 
  Wilson noted that the two leading problems in NTD inno-
vation are closely related: the lack of incentives for R&D 
and price as a barrier to access after drugs are developed. 
He proposed that the primary existing incentive for com-
mercial investment in pharmaceutical R&D—a partial mar-
ket monopoly afforded by patent protection—underlies both 
problems in that the size of the incentive depends not on pub-
lic health need but on market size, which is almost by defini-
tion small for NTDs, and that it works by increasing product 
prices. Strategies for driving development of health technolo-
gies for NTDs must provide an alternative source of funds for 
R&D.  39  
  In general, according to Wilson, incentives for R&D can be 
divided into two classes: push incentives, which reduce upfront 
risk and cost, and pull incentives, which increase the reward 
for successful R&D, supplementing or substituting for mar-
ket returns.  40   Some new ideas implemented to date include 
advance market commitments, prizes, and priority review 
vouchers (pull) as well as grants and other contracts that pay 
for research and agreements with PDPs that channel grant 
funding and reduce risk (push). 
  A major advantage of prizes that Wilson pointed out is to 
allow for crowd-sourcing, linking funders to those people with 
workable ideas; this route circumvents a common information 
asymmetry in which R&D funders do not know who has the 
best ideas   a priori . 41   The prize-giving organization does not 
have to specify the players or the path to the goal but only 
has to create a large reward and let the market try multiple 
solutions. When the path to an R&D solution (i.e., a promising 
drug candidate) and a qualified developer are better known, 
suggests Wilson, this advantage of prizes is less relevant, and 
a grant or a more traditional funding mechanism may be 
more appropriate. Still, one drawback of prizes is that product 
developers need to be able to raise upfront R&D funding; this 
requirement almost certainly excludes some innovators with 
promising ideas.  42  
  For academic researchers, Wilson reminded, raising funds to 
pursue an R&D prize is difficult unless existing grants would 
cover these costs, which would negate some of the advantages 
of the prize. Commercial innovators, who can fund R&D from 
existing revenues or raise venture capital, may be the most 
promising candidates for prizes. Universities, however, could 
participate through sponsored research programs and       licens-
ing intellectual property to companies pursuing prizes. 
  Wilson drew attention to his report on prizes for NTD R&D 
written in collaboration with The Results for Development 
Institute (R4D).  43   A case study of several prize propos-
als for TB diagnostics—including one developed in part 
by Knowledge Ecology International and another designed 
by the X-Prize Foundation, a prize-creating organization 
that has managed successful prize contests in other areas of 
technology—found that prizes likely would be useful in stim-
ulating innovation in this area. The R4D analysis concluded 
that inclusion of milestone awards, payments for achieve-
ment of significant interim steps on the path to an approved 
product, would make the incentive more attractive to 
small companies that would not otherwise afford additional 
R&D. 
  Wilson left us with a question for additional exploration: 
the scalability of prizes.  43   Sustaining a stream of innovation for 
NTDs would require an on-going series of prize contests, each 
of which would involve substantial investment and expertise 
to design and manage. This issue may be an argument for inte-
grated prize funds covering a range of products. In either case, 
a sustainable source of funding will be required. 
  Paul Converse (Research Associate, Johns Hopkins 
University School of Medicine) presented on the topic of 
improving resources within the university for NTDs based on 
insights from decades of experience in NTD research. 70 MUSSELWHITE AND OTHERS
  First, Converse addressed generating and sustaining inter-
est for NTD research in the academic community. He noted 
that the Johns Hopkins University (JHU) Bloomberg School 
of Public Health—which came to exist during a heyday of 
research in parasitology, bacteriology, and viral diseases—was 
originally founded with a Rockefeller Foundation grant to 
deal with the domestic NTD hookworm, known as Southern 
laziness.  44   NTD support waned, however, as public perception 
of infectious diseases as a threat declined into the late 1970s. 
  The 1980s and the emergence of HIV brought change. After 
decades of neglect, Converse claimed, the focus within the 
infectious disease community shifted from hospital-acquired 
diseases to HIV, NTDs, and other diseases affecting neglected 
populations. Johns Hopkins University kept pace by launch-
ing a certificate course in tropical medicine, a TB center, and a 
private fund to sponsor travel grants to developing countries. 
Multiuniversity initiatives began with a consortium of univer-
sities addressing HIV launched by universities in Pittsburgh, 
Chicago, and Los Angeles in collaboration with JHU. 
  Converse outlined three strategies to mobilize resources for 
NTD research. First, horizontal sourcing allows piggybacking 
onto related funding opportunities. For example, his colleagues 
have tapped into funding from the American Cancer Society 
to fund research for the NTD schistosomiasis, which can lead 
to bladder cancer. Second, small funders may lead to unortho-
dox sources of support, sometimes with unique requirements 
(such as, Converse recalled anecdotally, translating work into 
the operational language of the grantor). The Community of 
Science  45   was pointed out as a useful tool to publicize these 
opportunities.  46   Third, larger NTD-focused programs, such as 
the New Aid Foundation,  47   Innocentive, 48   and the Tres Cantos 
NTD-focused laboratory of GlaxoSmithKline,  49   although new 
and yet to show their promise, have—in his opinion—begun to 
show an impressive commitment to open innovation models 
of collaboration. 
  Converse also addressed three hurdles in securing NTD 
research funding. First, academic administrators tend to pre-
fer that faculty seek funding which, like NIH grants, provides 
support for university overhead costs. Second, granting bod-
ies prefer to fund projects with preliminary data, which is, by 
definition, often unavailable in NTD research. Converse here 
provided an anecdotal account of his own arduous journey to 
finally securing NIH funding.  50   Finally, significant challenges 
stymie the international collaboration needed to involve dis-
ease-endemic areas. Converse spoke from his experience in 
Ethiopia in the 1980s in a laboratory plagued by brain drain 
of Ethiopian staff and students. In addition, he bemoaned 
the difficulty of gathering a critical mass of visiting investiga-
tors willing to spend significant time, interact, and collaborate 
with local scientists. In particular, short-term research stints of 
1 week or less were more common but in Converse’s opinion, 
counterproductive. 
  Sandeep Kishore (MD/PhD Candidate, Weill-Cornell 
Medical College/The Rockefeller University/Sloan-Kettering 
Institute) presented reflections on students, NTD research, 
and community building at a university from his vantage point 
as a graduate student researcher. 
  Kishore told a moving personal account of losing a personal 
mentor to cerebral malaria in India as well as his own bout 
with the disease with a recovery aided by access to essential 
medicines. He devoted his PhD to battling NTDs; however, 
he judges that the current outlook for the current pipeline of 
academic NTD research trainees is not good. Some university 
department chairs still do not value global health, and career 
opportunities seldom reward students’ passion and vigor. 
  To address this problem, Kishore suggests reevaluat-
ing academic contributions according to global impact. 
Complementary metrics for success should consider health 
outcomes in addition to publications for both tenure deci-
sions and postgraduate student progression requirements. He 
encouraged students to take the lead when possible. As an 
example, Kishore described how he successfully lobbied his 
graduate program to waive one-half of his graduation course 
requirements in recognition of his work, categorized as inde-
pendent study, in service to the UAEM Board of Directors 
and the WHO Essential Medicines List. Meanwhile, unaffili-
ated global health experts can move to influence academia by 
seeking adjunct professor status at universities to help facili-
tate engagement with the next generation of NTD leaders. 
  Education sensitizes trainees to issues of global health and 
NTDs. At Cornell, a large medical campus event featuring 
global health leaders drew an audience of hundreds and left 
a lasting influence, garnering the support of both the Dean of 
Medicine and the University President. After the event, the 
student organizers developed an elective course in global 
health at the behest of medical school administrators. The 
course spanned health economics, basic science, clinical medi-
cine, nutrition, and population health and was attended by an 
impressive 30% of the medical school class. 
  The curriculum should also focus on interplay of poverty 
and NTDs with chronic and noncommunicable diseases, such 
as cardiovascular disease, depression, asthma, cancer, and 
even injury. Classifications of diseases as infectious or non-
communicable are limiting, because illnesses influence each 
other. The NTD Chagas disease is a driver of cardiac myopa-
thy, for instance, and schistosomiasis pre-disposes to bladder 
cancer. Conversely, noncommunicable diseases such as dia-
betes can pre-dispose a patient to acquiring an infectious dis-
ease. Furthermore, such risk factors as tobacco use negatively 
affect health outcomes for patients regardless of the disease 
etiology. At universities, such considerations should influence 
both the clinic and the research laboratory. The Molecules to 
Humankind PhD program at Emory, for example, combines 
laboratory and population sciences.  51   To accomplish this task 
at other institutions, Kishore ventured, would require a funda-
mental shift in an academic culture that may view population 
science as less rigorous. 
  Kishore also spoke of working together with students in 
the Global South. He spoke glowingly of communications 
with his UAEM colleague Evance Mbando, who runs the first 
student-led non-governmental organization (NGO) focused 
on NTDs in Tanzania at Weill Bugando, a medical college 
affiliated with Cornell. Institutions; also, individuals can help 
spread knowledge and models for activism, he stressed, citing 
the Cornell-Groupe Haitien d’Etude du Sarcome de Kaposi 
et des Infection Opportunistes       partnership in Haiti as addi-
tional evidence. 
   OS  INITIATIVES 
  This panel explored the role of OS initiatives and open 
access (OA) publishing for university- and government-
funded research to address global access to information and 
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  Heather Joseph (Executive Director, Scholarly Publishing 
and Academic Resources Coalition) opened the panel by 
defining the mission of scientific research as stimulating novel 
discoveries to influence how people within society think and 
interact with the world. She argued that the communication 
of research is, therefore, inseparable from the need to conduct 
research itself. Furthermore, she asserted that OA publication 
of scientific discovery should be the norm, not the alternative. 
  Joseph noted that research communications take place 
primarily through scholarly journals, most of which are not 
widely available. She posed that the single greatest barrier to 
OA publication is cost. One year of leased online access to a 
journal often exceeds tens of thousands of US dollars annu-
ally. She argued that even the best-funded libraries, such as 
the library at the Massachusetts Institute of Technology, do 
not have the financial resources available to subscribe to the 
breadth of journals necessary to conduct research effectively. 
  Joseph acknowledged that barriers exist, in part, because 
the academic science publishing industry is lucrative. In 2008, 
science, technology, and medical journal revenues approxi-
mated $8 billion. Although she asserted that price was the 
main obstacle to the implementation of OA publishing, the 
explosion of information in the last decade played a role as 
well, because the scientific community was still developing the 
technological resources to process exponentially increasing 
amounts of information. 
  Joseph stated that OA journals are relatively new and need 
time and support to become established and respected within 
the scientific community. Furthermore, she reasoned that busi-
ness models for OA journals require testing and refinement, 
whereas cultural change is also required within the scientific 
community. She believes that the current emphasis on effec-
tive communication of scientific findings and viewing pub-
lished results is insufficient. To enable this shift to take place, 
she believes authors need training on copyright practices to 
allow them to make rational choices regarding restrictions 
versus non-restrictions for their protected information. The 
Creative Commons set of licenses could be substituted for tra-
ditional copyright agreements.  52  
  In line with this principle, Joseph explained that universities 
were using collective bargaining power to challenge exclusive 
copyright of publishers. Harvard, for example, retained non-
exclusive worldwide distribution rights to place articles pub-
lished by its researchers in an OA online digital repository. 
Finally, she closed with the assertion that a universal definition 
of OA methods is urgently needed and offered the following: 
“The right to access information freely on the Internet and a 
legal right to interact with material in a robust way.” 
  Zakir Thomas (Project Director, Open Source Drug 
Discovery [OSDD]) spoke on the initiative established by 
the Indian Council of Scientific and Industrial Research 
and funded by a $45 million US grant from the Indian gov-
ernment.  53   Its aim is to foster innovation in a process-driven 
manner, with OS methods used to avoid encumbrance by tra-
ditional intellectual property approaches.  54   The Indian govern-
ment chose to begin the initiative with a TB project because 
of the large disease burden in India. Two deaths caused by TB 
occur in India every 3 minutes, and the global TB drug mar-
ket is $300 million, an insufficient amount to offset the risk of 
traditional drug development. OSDD sought to harness OS 
resources for a small-molecule open repository to allow aca-
demics to contribute compounds. 
  A proof of concept project took place, with a team of sci-
entists in collaboration with students annotating the entire 
genome of   Mycobacterium tuberculosis   in 6 months. In that 
time, volunteers made custom database formats to allow 
interoperability, and most work was done by online collabo-
ration. Students who contributed significantly were made 
authors. A self-organized hierarchy of scientific discovery 
emerged: in some cases, graduate students were leading group 
tasks online, whereas faculty members were group members. 
This online community annotated and self-corrected the entire 
genome by December of 2009 by contributing approximately 
300 man-years within a 4-month period. Additional OSDD 
projects will be funded after peer review, with funds dispersed 
within 30 days to streamline grant reviews and the award allo-
cation process. The OSDD initiative currently has 4,500 mem-
bers from more than 130 countries. 
  Rebecca Goulding (ISIS       Research Center, Sauder School 
of Business, University of British Columbia) outlined open 
innovation in NTD research, noting that this particular area 
of R&D uses innovative intellectual property strategies to 
achieve goals of discovery and improve access to these dis-
coveries. For example, an OS-style approach is used by Sage 
BioNetworks to integrate and share genomic and clinical data 
that can be used by a large community of researchers to build 
bionetwork models of disease for drug target discovery.  55  
  The concept of OS arose from the free software movement, 
which developed the General Public License (GPL) to allow 
users to access and make improvements to copyrighted source 
code and openly redistribute the improved version.  56  The GPL 
approach, therefore, reverses intellectual property protection 
(copyright is automatic) by imposing a copyleft license. In 
return, the GPL requires that the modified source code of sub-
sequent versions be distributed under the same GPL terms. 
This viral aspect of OS licenses acts to socially engineer desir-
able collaborative outcomes by requiring additional sharing of 
software improvements. Commercially, the OS software busi-
ness model often relies on the sale of services associated with 
the software. 
  Adaptation of OS to biotechnology/biomedicine has been 
explored in depth by a number of scholars and has been tested 
by a number of initiatives, including BiOS/Cambia,  57,  58   Open 
Source Drug Discovery,  59  and the Tropical Disease Initiative.  60,  61  
OS in biomedicine could take different forms, with either a viral 
license or an academic license that has few impositions other 
than to protect the original shared data or patented invention. 
A potential business model for OS in biomedicine could incor-
porate a value-added, service-based approach like in the OS 
software industry, although this approach would need tailoring 
to each invention in question. The use of viral terms, however, 
may not be applicable for some inventions such as drug targets 
and compounds, because OS requirements of this nature may 
dissuade R&D investment, which is currently based on strong 
IP protection and market monopoly models.  62  
  Mat Todd (Cofounder, Synaptic Leap; School of Chemistry, 
The University of Sydney, Australia) described an OS scien-
tific community collaborative that aimed to address difficult 
problems in biomedical research. 
  In January of 2007, the WHO approached Todd to syn-
thesize a low-cost, more pure version of praziquantel, the 
mainstay therapy for treating the NTD schistosomiasis. The 
presently manufactured form of praziquantel is a chemical 
mixture with a bitter taste, leading to dosing limitations and 72 MUSSELWHITE AND OTHERS
medication adherence difficulties, particularly among pediatric 
patients.  
  Todd emphasized that financial incentives to improve exist-
ing drugs are limited. Furthermore, he explained that drugs 
used to treat diseases primarily affecting marginalized popula-
tions have a limited commercial market, which adds another 
dimension of complexity to an already difficult task. He noted 
that improved formulations must also have a low cost of man-
ufacture to attract drug companies serving low- and middle-
income countries. With these challenges in mind, Todd and 
colleagues founded the website The Synaptic Leap. At the 
time, publishing raw experimental data online was rare and 
in mainstream sciences such as organic chemistry, is not com-
mon practice. The Synaptic Leap project received a 3-year 
$350,000 grant from the WHO and the Australian government 
to create methods for collaborating on data in experimental 
science. 
  The praziquantel chemistry problem is academically chal-
lenging and too complex for a single laboratory or researcher 
to solve within a reasonable time frame. With an open collab-
orative framework in place, multiple companies contributed 
to the project, including Dutch-based Syncom B.V.  63   A  major 
benefit of open science was realized: transparency of all data 
permitted accountability to fellow researchers and the pub-
lic, the funder behind much academic research. Furthermore, 
by allowing any individual or entity to contribute to the 
project and giving appropriate incentives/credit, the prob-
lem is potentially attractive in the academic and commercial 
sectors. 
  In retrospect, the commercial sector made the most signifi-
cant contributions to the project. Their help likely arose from 
company and individual investigator pride, the good public 
relations opportunity, and the open problem that most have 
a genuine interest in solving. Improved software is needed to 
make online collaboration as effective as communicating in 
person. Universities have been hesitant to buy into this struc-
ture. Reward incentives in academia tend to reward high-
impact journal publications, and many academic journals 
do not accept scientific results communicated in the public 
domain before formal publication, although some reputable 
journals (e.g., those published by   PLoS   and   BioMedCentral ) 
have begun to reverse this policy. 
  Ultimately, Todd reported that the OS collaborative effort 
was a success. The research was accelerated, because it was 
OS—people unknown to the team at the outset of the proj-
ect spontaneously contributed expertise. With major contribu-
tions from industry, a novel solution to the preparation of the 
drug has been proposed that may revolutionize treatment of 
the 200 million people with schistosomiasis. 
   CONCLUSION 
  The symposium ended with an open discussion of future 
policy directions and advocacy to most effectively lever-
age university resources, including scientific information, to 
enhance scientific innovation, particularly for NTDs.   Tables 1   
and   2   highlight the consensus reached among symposium 
participants on questions regarding the role of public sector 
research institutions in advancing NTD research. 
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  Table  1 
    What are the most effective roles for universities and public research 
institutions in biomedical innovation, particularly for       NTDs?   
Roles
Support equitable access to biomedical products developed at 
universities and public research institutions, including medicines, 
diagnostics, and vaccines
Promote OS science and non-market–driven, need-based research
Ensure the sustainability of neglected diseases research programs 
with supportive research budgets
Rethink the goals of technology commercialization to focus on 
access rather than financial revenues
Develop an outcome metrics system to appraise the public benefit of 
research conducted
Examine tenure track methodologies to ensure that they do not 
indirectly discourage NTD research, particularly among young 
scholars
Improve the risk to benefit ratio for young scientists to pursue the 
field of NTD research
Strengthen the Statement of Principles and Strategies and encourage 
its use in technology transfer agreements
Promote innovative policy ideas such as prize funds and OSDs and 
integrate these ideas with current technology transfer practices
  Table  2 
    For public research institutions, what are the best practices to use to 
advance NTD innovation?   
Best practices
Improve transparency in licensing terms
Minimize milestone payment fees for licensing of technologies 
related to NTDs or in instances when doing so could be 
detrimental for non-profit research institutions
Invest transferred technology licensing royalties back in funding 
NTD research
Highlight the successes and failures of NTD research to major R&D 
stakeholders, including the general public and funding entities
Promote non-patent methods to transfer technology when appropri-
ate, which may reduce market costs of the technology
Use open licensing clauses to allow for sublicensing or at-cost 
provisions whenever possible73 UAEM 2010 NEGLECTED DISEASES AND INNOVATION SYMPOSIUM
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